Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indication is a more rapid and less expensive option. Therefore, we apply the scaffold searching approach based on known amyloid-beta (Aβ) inhibitor tramiprosate to screen the DrugCentral database (n = 4,642) of clinically tested drugs. As a result, menadione bisulfite and camphotamide substances with protrombogenic and neurostimulation/cardioprotection effects were identified as promising Aβ inhibitors with an improved binding affinity (ΔGbind) and blood-brain barrier permeation (logBB). Finally, the data was also confirmed by molecular dynamics simulations using implicit solvation, in particular as Molecular Mechanics Generalized Born Surface Area (MM-GBSA) model. Overall, the proposed in silico pipeline can be implemented through the early stage rational drug design to nominate some lead candidates for AD, which will be further validated in vitro and in vivo, and, finally, in a clinical trial.
Citations by journals
1
2
|
|
Biomolecules
|
Biomolecules
2 publications, 18.18%
|
Journal of Cellular Biochemistry
|
Journal of Cellular Biochemistry
1 publication, 9.09%
|
Cells
|
Cells
1 publication, 9.09%
|
Frontiers in Chemistry
|
Frontiers in Chemistry
1 publication, 9.09%
|
Journal of Biomolecular Structure and Dynamics
|
Journal of Biomolecular Structure and Dynamics
1 publication, 9.09%
|
International Urology and Nephrology
|
International Urology and Nephrology
1 publication, 9.09%
|
Pharmaceutics
|
Pharmaceutics
1 publication, 9.09%
|
ACS Omega
|
ACS Omega
1 publication, 9.09%
|
Polymers
|
Polymers
1 publication, 9.09%
|
Future Medicinal Chemistry
|
Future Medicinal Chemistry
1 publication, 9.09%
|
1
2
|
Citations by publishers
1
2
3
4
5
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
5 publications, 45.45%
|
Wiley
|
Wiley
1 publication, 9.09%
|
Frontiers Media S.A.
|
Frontiers Media S.A.
1 publication, 9.09%
|
Taylor & Francis
|
Taylor & Francis
1 publication, 9.09%
|
Springer Nature
|
Springer Nature
1 publication, 9.09%
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
1 publication, 9.09%
|
Future Medicine
|
Future Medicine
1 publication, 9.09%
|
1
2
3
4
5
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.